000163540 001__ 163540
000163540 005__ 20230915092422.0
000163540 0247_ $$2doi$$a10.3389/fnagi.2021.722830
000163540 0247_ $$2pmid$$apmid:34916920
000163540 0247_ $$2pmc$$apmc:PMC8669821
000163540 0247_ $$2altmetric$$aaltmetric:117850601
000163540 037__ $$aDZNE-2022-00300
000163540 041__ $$aEnglish
000163540 082__ $$a610
000163540 1001_ $$aAtrsaei, Arash$$b0
000163540 245__ $$aEffect of Fear of Falling on Mobility Measured During Lab and Daily Activity Assessments in Parkinson's Disease.
000163540 260__ $$aLausanne$$bFrontiers Research Foundation$$c2021
000163540 3367_ $$2DRIVER$$aarticle
000163540 3367_ $$2DataCite$$aOutput Types/Journal article
000163540 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1689166110_3267
000163540 3367_ $$2BibTeX$$aARTICLE
000163540 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163540 3367_ $$00$$2EndNote$$aJournal Article
000163540 520__ $$aIn chronic disorders such as Parkinson's disease (PD), fear of falling (FOF) is associated with falls and reduced quality of life. With inertial measurement units (IMUs) and dedicated algorithms, different aspects of mobility can be obtained during supervised tests in the lab and also during daily activities. To our best knowledge, the effect of FOF on mobility has not been investigated in both of these settings simultaneously. Our goal was to evaluate the effect of FOF on the mobility of 26 patients with PD during clinical assessments and 14 days of daily activity monitoring. Parameters related to gait, sit-to-stand transitions, and turns were extracted from IMU signals on the lower back. Fear of falling was assessed using the Falls Efficacy Scale-International (FES-I) and the patients were grouped as with (PD-FOF+) and without FOF (PD-FOF-). Mobility parameters between groups were compared using logistic regression as well as the effect size values obtained using the Wilcoxon rank-sum test. The peak angular velocity of the turn-to-sit transition of the timed-up-and-go (TUG) test had the highest discriminative power between PD-FOF+ and PD-FOF- (r-value of effect size = 0.61). Moreover, PD-FOF+ had a tendency toward lower gait speed at home and a lower amount of walking bouts, especially for shorter walking bouts. The combination of lab and daily activity parameters reached a higher discriminative power [area under the curve (AUC) = 0.75] than each setting alone (AUC = 0.68 in the lab, AUC = 0.54 at home). Comparing the gait speed between the two assessments, the PD-FOF+ showed higher gait speeds in the capacity area compared with their TUG test in the lab. The mobility parameters extracted from both lab and home-based assessments contribute to the detection of FOF in PD. This study adds further evidence to the usefulness of mobility assessments that include different environments and assessment strategies. Although this study was limited in the sample size, it still provides a helpful method to consider the daily activity measurement of the patients with PD into clinical evaluation. The obtained results can help the clinicians with a more accurate prevention and treatment strategy.
000163540 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000163540 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000163540 650_7 $$2Other$$agait
000163540 650_7 $$2Other$$ainertial sensor
000163540 650_7 $$2Other$$asit-to-stand
000163540 650_7 $$2Other$$atimed-up and go
000163540 650_7 $$2Other$$aturning
000163540 650_7 $$2Other$$awearables
000163540 7001_ $$aHansen, Clint$$b1
000163540 7001_ $$0P:(DE-2719)9000064$$aElshehabi, Morad$$b2
000163540 7001_ $$0P:(DE-2719)2810733$$aNußbaum, Susanne$$b3$$udzne
000163540 7001_ $$0P:(DE-2719)2000059$$aBerg, Daniela$$b4
000163540 7001_ $$0P:(DE-2719)2109499$$aLiepelt-Scarfone, Inga$$b5
000163540 7001_ $$0P:(DE-2719)2810915$$aMaetzler, Walter$$b6
000163540 7001_ $$aAminian, Kamiar$$b7
000163540 773__ $$0PERI:(DE-600)2558898-9$$a10.3389/fnagi.2021.722830$$gVol. 13, p. 722830$$p722830$$tFrontiers in aging neuroscience$$v13$$x1663-4365$$y2021
000163540 8564_ $$uhttps://pub.dzne.de/record/163540/files/DZNE-2022-00300.pdf$$yOpenAccess
000163540 8564_ $$uhttps://pub.dzne.de/record/163540/files/DZNE-2022-00300.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000163540 909CO $$ooai:pub.dzne.de:163540$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000163540 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000064$$aExternal Institute$$b2$$kExtern
000163540 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810733$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000163540 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000059$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000163540 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2109499$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000163540 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2810915$$aExternal Institute$$b6$$kExtern
000163540 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000163540 9141_ $$y2021
000163540 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-01-27
000163540 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-27
000163540 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-27
000163540 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-27
000163540 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-01-27
000163540 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000163540 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-27
000163540 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT AGING NEUROSCI : 2021$$d2022-11-30
000163540 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-30
000163540 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-30
000163540 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-13T09:17:03Z
000163540 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-13T09:17:03Z
000163540 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-05-13T09:17:03Z
000163540 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-30
000163540 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-30
000163540 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-30
000163540 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bFRONT AGING NEUROSCI : 2021$$d2022-11-30
000163540 9201_ $$0I:(DE-2719)5000055$$kAG Berg$$lParkinson's Disease Genetics$$x0
000163540 9201_ $$0I:(DE-2719)1240005$$kCore ICRU$$lCore ICRU$$x1
000163540 9201_ $$0I:(DE-2719)1210000$$kAG Gasser 2 ; AG Gasser 2$$lParkinson Genetics$$x2
000163540 980__ $$ajournal
000163540 980__ $$aVDB
000163540 980__ $$aI:(DE-2719)5000055
000163540 980__ $$aI:(DE-2719)1240005
000163540 980__ $$aI:(DE-2719)1210000-7
000163540 980__ $$aUNRESTRICTED
000163540 9801_ $$aFullTexts